Objective
This study aims to uncover preferences of T1D patients and providers towards adjunctive therapies including perceived unmet needs and treatment priorities and tradeoffs to ultimately drive new therapy development and better T1D patient outcomes. Key objectives include: identifying the key factors that drive patient and preferences and decision-making for T1D adjunctive therapies, characterizing T1D provider preferences and treatment decision-making drivers for T1D adjunctive therapies, and developing the target product profile(s) and target T1D patient profile(s) for adjunctive therapy.
Background Rationale
T1D requires comprehensive treatment beyond insulin therapy due to metabolic disorder complexities, with current insulin therapy often failing to achieve optimal glycemic control. Adjunctive metabolic therapies have the potential to address other metabolic challenges faced by T1D patients, such as dysregulated glucagon, insulin resistance, and obesity, with the aim of improving glycemic targets, reducing insulin requirements, and enhancing quality of life. However, studies show limited adoption of adjunct therapies in T1D, driven by regulatory barriers and a lack of targeted industry investment compared to other metabolic diseases. Breakthrough T1D seeks to conduct a human subjects observational global research study with the intent of publishing findings in a peer-reviewed journal to accelerate the development of metabolic therapies for T1D that can improve glucometabolic control and mitigate long-term complications.
Description of Project
Breakthrough T1D seeks to conduct a research study, with the intent of publishing findings in a peer-reviewed journal, to better understand target product and patient profiles for T1D adjunct therapy for the end goal of accelerating the development of metabolic therapies that can improve glucometabolic control and mitigate long-term complications in T1D.
Anticipated Outcome
Patient- and provider-driven insights into the top priorities for an adjunct therapy for T1D including, most important treatment attributes (including perceived tradeoffs between treatment attributes), target thresholds of treatment outcomes, and the optimal product profile(s) that would maximize interest/adoption. Research will also provide clear patient profiles to better characterize the market opportunity for adjunct therapy.
Relevance to T1D
This research intends to uncover the priorities of individuals with Type 1 Diabetes as well as their providers to inform and expedite the research and development of adjunctive therapies, ultimately for the goal of improving T1D patients' quality of life and long-term outcomes.